Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.41 |
| ▸ | S100A4 | P26447 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 2/20 | 0.36 |
| ▸ | FABP3 | P05413 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL756963 | 0.86 | FFAR1 (0.45) | FFAR1FFAR4PTGDR2S100A4KMT2A | |
| SCHEMBL3746249 | 0.80 | FFAR1 (0.50) | FFAR1FFAR4PTGDR2KMT2AMEN1 | |
| SCHEMBL3746360 | 0.78 | FFAR4 (0.66) | FFAR1FFAR4PTGDR2 | |
| SCHEMBL13321613 | 0.77 | FLT1 (0.38) | KMT2AMEN1CYP3A4HPGDALOX15 | |
| SCHEMBL27600768 | 0.77 | IDO1 (0.47) | KMT2AMEN1CYP3A4HPGDALOX15 | |
| SCHEMBL14686251 | 0.77 | FFAR1 (0.49) | FFAR1FFAR4PTGDR2KMT2AMEN1 | |
| SCHEMBL759109 | 0.76 | FFAR1 (0.46) | FFAR1FFAR4PTGDR2S100A4KMT2A | |
| SCHEMBL31464099 | 0.76 | FFAR1 (0.46) | FFAR1FFAR4PTGDR2S100A4KMT2A | |
| SCHEMBL4706651 | 0.76 | IDO1 (0.46) | KMT2AMEN1CYP3A4HPGDALOX15 | |
| SCHEMBL27417857 | 0.75 | FFAR1 (0.48) | FFAR1FFAR4PTGDR2S100A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670766-B1 | Bicyclic imino acid derivatives for the treatment of (inter alia) diseases relating to the locomotor system | SANOFI AVENTIS DEUTSCHLAND (DE) | 2012-03-21 | — | — | EP | disclosed |
| US-20070203118-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-30 | — | — | US | disclosed |
| US-7205315-B2 | Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-17 | — | — | US | disclosed |
| EP-1763516-A2 | SUBSTITUTED TETRAHYDROISOCHINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRAGS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-03-21 | — | — | EP | disclosed |
| EP-1670766-A1 | BICYCLIC IMINO ACID DERIVATIVES USED AS INHIBITORS OF MATRIX-METALLOPROTEINASES | Sanofi-Aventis Deutschland GmbH (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2006002763-A2 | SUBSTITUTED TETRAHYDROISOCHINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRAGS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-01-12 | — | — | WO | disclosed |
| US-20050080127-A1 | Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-04-14 | — | — | US | disclosed |
| WO-2005030728-A1 | BICYCLIC IMINO ACID DERIVATIVES USED AS INHIBITORS OF MATRIX-METALLOPROTEINASES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080127-A1 | Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases | MMP1, MMP17, MMP25 | FFAR1 2951/4885FFAR4 4232/4885PTGDR2 499/4885 |
| US-20070203118-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | MMP9, MMP2, MMP3 | FFAR1 3332/4885FFAR4 3662/4885PTGDR2 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.